Lantheus Receives FDA Tentative Approval for New Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy LNTH?
Source: Newsfilter
- FDA Tentative Approval: Lantheus has received FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), marking a significant advancement in treatment options for GEP-NETs, which is expected to enhance patient outcomes.
- Market Potential: With approximately 200,000 patients in the U.S. suffering from GEP-NETs, the increasing identification of patients due to advancements in imaging technology positions PNT2003 to meet the growing demand for targeted radiopharmaceutical therapies.
- Patent Litigation Impact: The full FDA approval of PNT2003 is contingent upon the expiration of a 30-month stay in June 2026, triggered by Hatch-Waxman patent litigation, which may affect the drug's market entry timeline.
- Global Exclusive License: Lantheus licensed exclusive worldwide rights to PNT2003 from POINT Biopharma Global in December 2022, further solidifying its leadership in the radiopharmaceutical sector and laying the groundwork for future market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LNTH
Wall Street analysts forecast LNTH stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 78.840
Low
70.00
Averages
82.17
High
105.00
Current: 78.840
Low
70.00
Averages
82.17
High
105.00
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lantheus Receives FDA Tentative Approval for New Drug
- FDA Tentative Approval: Lantheus has received FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), marking a significant advancement in treatment options for GEP-NETs, which is expected to enhance patient outcomes.
- Market Potential: With approximately 200,000 patients in the U.S. suffering from GEP-NETs, the increasing identification of patients due to advancements in imaging technology positions PNT2003 to meet the growing demand for targeted radiopharmaceutical therapies.
- Patent Litigation Impact: The full FDA approval of PNT2003 is contingent upon the expiration of a 30-month stay in June 2026, triggered by Hatch-Waxman patent litigation, which may affect the drug's market entry timeline.
- Global Exclusive License: Lantheus licensed exclusive worldwide rights to PNT2003 from POINT Biopharma Global in December 2022, further solidifying its leadership in the radiopharmaceutical sector and laying the groundwork for future market expansion.
See More
Lantheus Holdings Under Investigation for Securities Violations
- Revenue Decline: Lantheus Holdings reported an 8% year-over-year decline in Pylarify revenue in August 2025, contrasting sharply with the company's previous optimistic outlook, which has diminished market confidence in its growth potential.
- Guidance Cut: The company also lowered its full-year guidance while facing widespread contract renegotiations and account losses, exacerbating investor concerns regarding its financial health and future performance.
- Legal Action: Lantheus and certain executives are facing a securities class action lawsuit for failing to disclose material information, which violates federal securities laws, and this ongoing litigation could have long-term implications for the company's reputation and stock price.
- Investigation Launched: Kahn Swick & Foti has initiated an investigation into whether Lantheus' officers and directors breached their fiduciary duties to shareholders, and if findings indicate wrongdoing, it could lead to further legal consequences.
See More
Lantheus Holdings Q4 2025 Earnings Call Insights
- Strategic Transformation: Lantheus Holdings completed acquisitions of Neuraceq and OCTEVY in Q4 2025, establishing a commercial cornerstone for its Alzheimer's portfolio, with Neuraceq projected to achieve 140% to 150% inorganic growth in 2026, indicating strong potential in the neuroimaging sector.
- Financial Performance: The company reported Q4 revenue of $406.8 million, a 4% year-over-year increase, with full-year revenue at $1.5416 billion, up 0.5%, while repurchasing $100 million in shares during the quarter, reflecting confidence in future growth and financial flexibility.
- Future Outlook: Lantheus forecasts global net revenue between $1.4 billion and $1.45 billion for 2026, despite an expected 8% to 10% decline in PYLARIFY's net revenue; the strategic focus on innovation and commercialization of PET diagnostics aims to optimize cost structures for long-term growth.
- Market Risks: Management identified pricing pressures and competitive dynamics in the PSMA PET imaging market as key risks, alongside uncertainties regarding regulatory approvals and integration of new products, emphasizing the need to optimize the value of therapeutic assets amid resource constraints.
See More
Lantheus Holdings Reviews 2025 Performance and Future Outlook
- Patient Impact: In 2025, Lantheus's products impacted approximately 7 million patients, underscoring the company's significance in the radiopharmaceutical sector and demonstrating the broad application and societal value of its offerings.
- Strategic Acquisitions: The company completed acquisitions of Neuraceq and OCTEVY, with the former becoming the cornerstone of its Alzheimer's portfolio, and is expected to grow faster than the overall market in 2026, enhancing Lantheus's competitive position in the rapidly expanding PET imaging market.
- Pipeline Expansion: Lantheus further strengthened its prostate cancer product portfolio, particularly with PYLARIFY's market leadership, which will lay the groundwork for the launch of a new formulation expected in Q4 2026, promising significant commercial impact.
- Financial Performance: In Q4 2025, Lantheus reported revenue of $406.8 million, a 4% year-over-year increase, despite a 6.5% decline in annual revenue from PYLARIFY, indicating the company's resilience in a highly competitive market.
See More
Mixed Earnings Reports Drive Stock Movements
- Smucker Earnings Beat: J.M. Smucker reported third-quarter earnings of $2.38 per share, exceeding the $2.27 expected by analysts, with revenue of $2.34 billion, resulting in a 7% stock price increase, indicating strong performance in the food sector.
- Nutanix Partnership Investment: Nutanix shares surged 19% following a multi-year partnership with AMD, which will invest $150 million in Nutanix to jointly develop an AI infrastructure platform, enhancing competitive positioning in the market.
- IonQ Optimistic Sales Projections: IonQ's stock jumped 12% after projecting first-quarter revenues between $48 million and $51 million, surpassing analysts' expectations of $36 million, showcasing strong growth potential in the quantum computing sector.
- Trade Desk Earnings Miss: Trade Desk's stock plummeted 16% as it forecasted first-quarter adjusted EBITDA of approximately $195 million, significantly below the $223 million expected by analysts, reflecting challenges in the advertising technology industry.
See More
Lantheus Reports Strong 2025 Financials, Shifts Focus to Radiodiagnostics
- Strong Financial Performance: Lantheus reported worldwide revenue of $406.8 million for Q4 2025, a 4.0% increase year-over-year, demonstrating the company's sustained market leadership, particularly in the PYLARIFY product line.
- Significant Profitability Improvement: GAAP earnings per share surged from a loss of $0.17 in the prior year to $0.82, reflecting a remarkable 578.8% increase, showcasing the company's success in cost control and operational efficiency.
- Strategic Focus Shift: The company announced a strategic pivot towards innovative radiodiagnostics, planning to drive long-term growth through acquisitions and the development of new products, especially in the PET radiodiagnostics sector.
- Optimistic Future Outlook: Lantheus projects 2026 revenue between $1.4 billion and $1.45 billion, with adjusted EPS guidance of $5.00 to $5.25, indicating strong confidence in future market opportunities.
See More
Lantheus Receives FDA Tentative Approval for New Drug
- FDA Tentative Approval: Lantheus has received FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), marking a significant advancement in treatment options for GEP-NETs, which is expected to enhance patient outcomes.
- Market Potential: With approximately 200,000 patients in the U.S. suffering from GEP-NETs, the increasing identification of patients due to advancements in imaging technology positions PNT2003 to meet the growing demand for targeted radiopharmaceutical therapies.
- Patent Litigation Impact: The full FDA approval of PNT2003 is contingent upon the expiration of a 30-month stay in June 2026, triggered by Hatch-Waxman patent litigation, which may affect the drug's market entry timeline.
- Global Exclusive License: Lantheus licensed exclusive worldwide rights to PNT2003 from POINT Biopharma Global in December 2022, further solidifying its leadership in the radiopharmaceutical sector and laying the groundwork for future market expansion.
See More
Lantheus Holdings Under Investigation for Securities Violations
- Revenue Decline: Lantheus Holdings reported an 8% year-over-year decline in Pylarify revenue in August 2025, contrasting sharply with the company's previous optimistic outlook, which has diminished market confidence in its growth potential.
- Guidance Cut: The company also lowered its full-year guidance while facing widespread contract renegotiations and account losses, exacerbating investor concerns regarding its financial health and future performance.
- Legal Action: Lantheus and certain executives are facing a securities class action lawsuit for failing to disclose material information, which violates federal securities laws, and this ongoing litigation could have long-term implications for the company's reputation and stock price.
- Investigation Launched: Kahn Swick & Foti has initiated an investigation into whether Lantheus' officers and directors breached their fiduciary duties to shareholders, and if findings indicate wrongdoing, it could lead to further legal consequences.
See More
Lantheus Holdings Q4 2025 Earnings Call Insights
- Strategic Transformation: Lantheus Holdings completed acquisitions of Neuraceq and OCTEVY in Q4 2025, establishing a commercial cornerstone for its Alzheimer's portfolio, with Neuraceq projected to achieve 140% to 150% inorganic growth in 2026, indicating strong potential in the neuroimaging sector.
- Financial Performance: The company reported Q4 revenue of $406.8 million, a 4% year-over-year increase, with full-year revenue at $1.5416 billion, up 0.5%, while repurchasing $100 million in shares during the quarter, reflecting confidence in future growth and financial flexibility.
- Future Outlook: Lantheus forecasts global net revenue between $1.4 billion and $1.45 billion for 2026, despite an expected 8% to 10% decline in PYLARIFY's net revenue; the strategic focus on innovation and commercialization of PET diagnostics aims to optimize cost structures for long-term growth.
- Market Risks: Management identified pricing pressures and competitive dynamics in the PSMA PET imaging market as key risks, alongside uncertainties regarding regulatory approvals and integration of new products, emphasizing the need to optimize the value of therapeutic assets amid resource constraints.
See More
Lantheus Holdings Reviews 2025 Performance and Future Outlook
- Patient Impact: In 2025, Lantheus's products impacted approximately 7 million patients, underscoring the company's significance in the radiopharmaceutical sector and demonstrating the broad application and societal value of its offerings.
- Strategic Acquisitions: The company completed acquisitions of Neuraceq and OCTEVY, with the former becoming the cornerstone of its Alzheimer's portfolio, and is expected to grow faster than the overall market in 2026, enhancing Lantheus's competitive position in the rapidly expanding PET imaging market.
- Pipeline Expansion: Lantheus further strengthened its prostate cancer product portfolio, particularly with PYLARIFY's market leadership, which will lay the groundwork for the launch of a new formulation expected in Q4 2026, promising significant commercial impact.
- Financial Performance: In Q4 2025, Lantheus reported revenue of $406.8 million, a 4% year-over-year increase, despite a 6.5% decline in annual revenue from PYLARIFY, indicating the company's resilience in a highly competitive market.
See More
Mixed Earnings Reports Drive Stock Movements
- Smucker Earnings Beat: J.M. Smucker reported third-quarter earnings of $2.38 per share, exceeding the $2.27 expected by analysts, with revenue of $2.34 billion, resulting in a 7% stock price increase, indicating strong performance in the food sector.
- Nutanix Partnership Investment: Nutanix shares surged 19% following a multi-year partnership with AMD, which will invest $150 million in Nutanix to jointly develop an AI infrastructure platform, enhancing competitive positioning in the market.
- IonQ Optimistic Sales Projections: IonQ's stock jumped 12% after projecting first-quarter revenues between $48 million and $51 million, surpassing analysts' expectations of $36 million, showcasing strong growth potential in the quantum computing sector.
- Trade Desk Earnings Miss: Trade Desk's stock plummeted 16% as it forecasted first-quarter adjusted EBITDA of approximately $195 million, significantly below the $223 million expected by analysts, reflecting challenges in the advertising technology industry.
See More
Lantheus Reports Strong 2025 Financials, Shifts Focus to Radiodiagnostics
- Strong Financial Performance: Lantheus reported worldwide revenue of $406.8 million for Q4 2025, a 4.0% increase year-over-year, demonstrating the company's sustained market leadership, particularly in the PYLARIFY product line.
- Significant Profitability Improvement: GAAP earnings per share surged from a loss of $0.17 in the prior year to $0.82, reflecting a remarkable 578.8% increase, showcasing the company's success in cost control and operational efficiency.
- Strategic Focus Shift: The company announced a strategic pivot towards innovative radiodiagnostics, planning to drive long-term growth through acquisitions and the development of new products, especially in the PET radiodiagnostics sector.
- Optimistic Future Outlook: Lantheus projects 2026 revenue between $1.4 billion and $1.45 billion, with adjusted EPS guidance of $5.00 to $5.25, indicating strong confidence in future market opportunities.
See More
